Ophthalmic Companies in Europe, Ophthalmic Companies in India, Ophthalmic Companies in Kazakasthan, Ophthalmic Companies in USA, Ophthalmic ProductsCyclomed® eye drops

Composition:

Each ml contains: Active agent: Cyclopentolate Hydrochloride of 10 mg Auxiliary components: Benzalkonium Chloride – 0.1 mg, Disodium EDTA; sodium chloride; Water for injections

Trade Name:

Cyclomed eye drops

Composition :

Each ml contains :

Active agent: Cyclopentolate Hydrochloride of 10 mg

Auxiliary components: Benzalkonium Chloride – 0.1 mg, Disodium EDTA; sodium chloride; Water for injections

Pharmacotherapeutic Group:

Mydriatic and cycloplegic; Anticholinergic drug

Indications:

  • For the diagnostic purposes: ophthalmoscopy; determination of refraction.
  • In the preoperation preparation: for dilation of pupil for the extraction of cataract.
  • In the inflammatory diseases of the front division of eye – episklerites, sclerites, keratites, iridocyclite, uveitis – in the composition of complex therapy.

Dosage and Administration:

opically Instill 1 – 2 drops into the conjunctival sac.
For the inspection of the ocular fundus: 1 drop 1 – 3 times a day with the interval of 10 minutes.
Study of refraction in children and adolescents: 1 – 2 drop 2 – 3 times a day with the interval of 15 – 20 minutes.
In the inflammatory diseases: 1 drop 3 times in the day, in the heavy cases 1 drop each 3 – 4 hours is permitted.

Contraindications:

  • Suspicion to the glaucoma; glaucoma.
  • Increased sensitivity to the preparation.

Warning and Precautions:

  • Children of up to 3 years; elderly age; intestinal impassability; hyperplasia of prostate gland

Adverse Effects:

Reddening of conjunctiva and the sensation of discomfort after instillation, temporary reduction in the visual acuity
Increase in the intraocular pressure in the patients with primary glaucoma.
Weakness, nausea, vertigo, tachycardia
In children sensitive to Cyclopentolate: general weakness, nausea, vertigo, sleepiness, dryness of the mouth, headache, in the rare cases tachycardia.

Drug Interaction:

Sympathomimetics (mesaton) can enhance the effect of application of Cyclomed, whereas M-cholinomimetics (pilocarpine) to weaken the effect.

Preparations with M-cholinomimetic properties taken simultaneously with Cyclomed can strengthen its side-effect actions.

Over Dosage:

With the precise following to the doctor’s instructions the cases of overdose were not observed. However, with exceeding of the recommended doses of preparation, and also in case of preparation’s oral intake, the following symptoms can be observed: dryness of the skin and of the mucous membranes, tachycardia, excitation and the disturbance of mental reactions (incoherent speech, fatigue, the disturbance of the recognition of the closely spaced objects and disorientation in the space, a change in the emotional state); with the very high doses paralysis of respiration and coma. Treatment: v/v introduction of specific antidote – physostigmine, to children at the dose of 0.5 mg. In the absence of effect during 5 minutes repeat the dose (maximum dose must not exceed 2.0 mg). Antidote is introduced to adult at the dose of 2.0 mg; in the absence of effect during 20 minutes repeat introduction at dose 1 – 2 mg

Other Related Information:

Cyclomed is less effective in the persons with the dark- pigment irides. In these persons with the use of preparation residual accommodation can reach 2 – 4 dioptrics.

In children when the semi-steadfast or steadfast spasm of accommodation is present, it is better to use atropine sulfate for cycloplegia.

During the application of Cyclomed in elderly patients the control of intraocular pressure is required. Patients with the increased sensitivity to the atropine do not give cross allergy to Cyclomed, which makes it possible to use it in this category of patients.

Against the background of the application of preparation one should restrain from control of transport and others potentially dangerous it is specific activity.

Pregnancy and lactation:

Since the action of preparation in the pregnant women and the feeding mothers is studied insufficiently, application in these categories of patients is possible, if the expected effect exceeds the risk of the development of possible side effects in fruit or child.

Packaging:

  • 5 ml into the plastic dropper vial with the screwed up cap. Each dropper vial with instruction on the application is placed into carton unit.
  • 5 ml into the bottle of dark glass. Each bottle with the dropper is placed into plastic sachet. Each plastic sachet with the instruction on the application is placed into carton unit.

Storage Conditions:

At a temperature to 25 °C in the place protected from the light and inaccessible for the children. Not to freeze!

Shelf-Life:

  • 2 years
  • 1 month after vial opening.